PD09
The cell line is not validated yet.
NIMHi027-A
General
Cell Line |
|
| hPSCreg name | NIMHi027-A |
| Cite as: | NIMHi027-A |
| Alternative name(s) |
PD09
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi037-A (IPSC0048, LRRK2 M1646T(CBIGi037-A)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi039-A (IPSC0050, LRRK2 R1441H(CBIGi039-A)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi040-A (IPSC0052, LRRK2 N551K-R1398H-K1423K (protective haplotype) (CBIGi040-A)) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi041-A (IPSC0053, GBA L444P (CBIGi041-A)) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi042-A (IPSC0055, GBA E326K (CBIGi042-A)) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi044-A (LRRK2 N551K-R1398H-K1423K (protective haplotype)(CBIGi044-A), IPSC0058) Donor's gene variants: LRRK2, LRRK2 Donor diseases: Parkinson Disease CBIGi045-A (GBA L444P(CBIGi045-A), IPSC0077) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi049-A (IPSC0093, SOD1 I144T(CBIGi049-A)) Donor's gene variants: SOD1, SOD1 Donor diseases: Amyotrophic Lateral Sclerosis |
| Last update | 8th October 2025 |
| User feedback | |
Provider |
|
| Generator | National Institute of Mental Health and Neurosciences (NIMH) |
| Owner | National Institute of Mental Health and Neurosciences (NIMH) |
| Distributors | |
| Derivation country | India |
External Databases |
|
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | INDIAN |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes | no phenotypes |
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | No |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | This work is supported by the Biotechnology Industry Research Assistance Council (BIRAC), Promoting Academic Research Conversion to Enterprise (PACE) scheme of grant number BIRAC/BT/AIR0252/PACE-12/17. Generation of induced pluripotent stem cells and midbrain floor plate cells from Indian ethnicity Parkinsons disease patients. |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | Yes |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | Yes |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | Yes |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | Yes |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | Yes |
| How may genetic information associated with the cell line be accessed? | Open Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | National Institute of Mental Health and Neurosciences - Institutional Ethics Committee 11th Meeting |
| Approval number | NIMHANS/IEC (BS & NS DIV.)11TH MEETING/2018 |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | National Institute of Mental Health and Neurosciences - Institutional Committee for Stem Cell Research |
| Approval number | SEC/01/005/BP |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Thermo Fisher Scientific |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Gelatin | ||||||||||||
| Feeder cells |
Mouse Embryonic Fibroblast Cellfinder Ont Id: CF_97 |
||||||||||||
| Passage method |
Enzymatically
Accutase
|
||||||||||||
| CO2 Concentration | 5 % | ||||||||||||
| Medium |
Other medium:
Base medium: Dulbecco's modified Eagle's medium F-12
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
||||||||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
||||||||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|
||
| TRA 1-60 |
Yes |
|
|
|
||
| NANOG |
Yes |
|
|
|
||
| SSEA-4 |
Yes |
|
|
|
||
| SOX2 |
Yes |
|
|
Differentiation Potency
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.